Boule Diagnostics AB (publ) (STO:BOUL)

Market Cap	46.21M -81.3%
Revenue (ttm)	430.29M -16.1%
Net Income	-17.25M
EPS	-0.45
Shares Out	38.83M
PE Ratio	n/a
Forward PE	8.24
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,302,995
Open	0.898
Previous Close	0.850
Day's Range	0.898 - 1.700
52-Week Range	0.840 - 6.640
Beta	0.31
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 23, 2026

About Boule Diagnostics AB

Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. It operates through Diagnostics and OEM Clinical Diagnostic Solutions. The company provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, and Medonic brands; and veterinary hematology and clinical chemistry analyzer systems, as well as reagents and panels under the Exigo brand. It ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1956
• Employees: 200
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: BOUL

Financial Performance

In 2025, Boule Diagnostics AB's revenue was 489.69 million, a decrease of -12.31% compared to the previous year's 558.46 million. Losses were -3.75 million, -98.73% less than in 2024.

Data Sources: S&P Global Market Intelligence and QUODD

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by QUODD.

Last checked:

Nov 4, 2026

Data Sources Report a data error